Abstract:Highlights • We report for the first time the synthesis and validation of ultra-small Fe-DMY NCPs particles formed by coupling DMY with low-toxicity iron ions. • In vitro and in vivo experiments confirmed its ability of alleviating oxidative stress damage to vascular endothelial cells by high glucose, scavenging overproduced ROS and ameliorating pathological features of DR such as retinal vascular leakage and neovascularization. • Mechanistic validation suggested that Fe-DMY NCPs could inhibit the activation of Poldip2-Nox4-H2O2 signaling pathway and down-regulate important vascular function indicators such as VCAM-1, HIF-1α and VEGF. • We proved that Fe-DMY NCPs may be a novel polymeric drug with therapeutic potential for DR as a safe and efficient antioxidant and microangio-protective agent. Diabetic retinopathy (DR) is a prevalent microvascular complication of diabetes and the leading cause of blindness and severe visual impairment in adults. The high levels of glucose trigger multiple intracellular oxidative stress pathways, such as POLDIP2, resulting in excessive reactive oxygen species (ROS) production and increased expression of VCAM-1, HIF-1α, and VEGF, causing microvascular dysfunction. Dihydromyricetin (DMY) is a natural flavonoid small molecule antioxidant. However, it exhibits poor solubility in physiological environments, has a short half-life in vivo, and has low oral bioavailability. In this study, we present, for the first time, the synthesis of ultra-small Fe-DMY nano-coordinated polymer particles (Fe-DMY NCPs), formed by combining DMY with low-toxicity iron ions. In vitro and in vivo experiments confirm that Fe-DMY NCPs alleviate oxidative stress-induced damage to vascular endothelial cells by high glucose, scavenge excess ROS, and improve pathological features of DR, such as retinal vascular leakage and neovascularization. Mechanistic validation indicates that Fe-DMY NCPs can inhibit the activation of the Poldip2-Nox4-H 2 O 2 signaling pathway and downregulate vital vascular function indicators such as VCAM-1, HIF-1α, and VEGF. These findings suggest that Fe-DMY NCPs could serve as a safe and effective antioxidant and microangio-protective agent, with the potential as a novel multimeric drug for DR therapy. Graphical abstract Schematic diagram of preparation process and DR protection of Fe-DMY NCPs. Ultrasmall Fe-DMY coordination polymer nanoparticles (Fe-DMY NCPs) are formed by coupling DMY with low toxic iron ions. Fe-DMY NCPs can reduce the oxidative stress damage of high glucose on vascular endothelial cells, eliminate excess ROS and improve the pathological characteristics of DR (such as retinal vascular leakage and neovascularization), inhibit the activation of Poldip2-Nox4-H 2 O 2 signal pathway, and down regulate important vascular function indicators, such as VCAM-1, HIF-1 α and VEGF. Fe-DMY NCPs may be a safe and effective antioxidant and microvascular protector, which has the potential to treat DR and is a new type of polymer drug. Download : Download high-res image (295KB) Download : Download full-size image

Facile fabrication of redox nanoparticles loaded with exosomal-miRNAs and resveratrol as glycation inhibitor in alleviating the progression and development of diabetic cataract

Autoregenerative redox nanoparticles as an antioxidant and glycation inhibitor for palliation of diabetic cataracts

Potential of CeCl 3 @msio 2 Nanoparticles in Alleviating Diabetic Cataract Development and Progression

Nanoceria for Ocular Diseases: Recent Advances and Future Prospects

Antioxidant and anti-glycated TAT-modified platinum nanoclusters as eye drops for non-invasive and painless relief of diabetic cataract in rats

Gold Nanoparticles Encapsulated Resveratrol as an Anti-Aging Agent to Delay Cataract Development

Cyclic RGD Conjugated PEG-PLGA Nanoparticle Enhances Preventative Effect of Bilirubin on the Development of Ultraviolet-B (Uvb)-Induced Cataract

Mitigation of lens opacification by a functional food in a diabetic rodent model

MicroRNA-204-5p Attenuates Oxidative Stress, Apoptosis and Inflammation by Targeting TXNIP in Diabetic Cataract

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization

The Synergistic Effects of Polyol Pathway-Induced Oxidative and Osmotic Stress in the Aetiology of Diabetic Cataracts

MSC-derived Small Extracellular Vesicles Mitigate Diabetic Retinopathy by Stabilizing Nrf2 Through Mir-143-3p-mediated Inhibition of Neddylation

Effects of Gold Nanoparticles Phytoreduced with Rutin in an Early Rat Model of Diabetic Retinopathy and Cataracts

Systemic Anti-Inflammatory Therapy Aided by Curcumin-Laden Double-Headed Nanoparticles Combined with Injectable Long-Acting Insulin in a Rodent Model of Diabetes Eye Disease

Cu-Doping Layered Double Hydroxides Nanozyme Integrated with Nitric Oxide Donor for Enhanced Antioxidant Therapy in Retinopathy

Efficiency co-delivery of ellagic acid and oxygen by a non-invasive liposome for ameliorating diabetic retinopathy

Nanoscale Coordination Polymer Fe-DMY Downregulating Poldip2-Nox4-H 2 O 2 Pathway and Alleviates Diabetic Retinopathy

Recent Progression of Pathogenesis and Treatment for Diabetic Cataracts

A kidney-targeted chitosan-melanin nanoplatform for alleviating diabetic nephropathy through modulation of blood glucose and oxidative stress

Investigation of synergistic mechanism and identification of interaction site of aldose reductase with the combination of gigantol and syringic acid for prevention of diabetic cataract

Dichloroacetate ameliorates apoptosis, EMT and oxidative stress in diabetic cataract via inhibiting the IDO1-dependent p38 MAPK pathway